<DOC>
	<DOCNO>NCT00717145</DOCNO>
	<brief_summary>Randomized , open-label , multi-center , 4-treatment , 4-period crossover study . The study consist screen visit , study center admission ( precede Treatment Periods 1 , 2 , 3 , 4 ) , 4 treatment period ( 4 day ) , 3 washout period ( 14 17 day duration separate treatment period ) , exit procedure .</brief_summary>
	<brief_title>Food Effects Relative Bioavailability Different Dosages Risedronate</brief_title>
	<detailed_description />
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>nonlactating either surgically sterile postmenopausal : body mass index less equal 32 kg/m2 screen No use bisphosphonate within 1 month history GI disease use medication within 714 day prior schedule dosing day</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>bioequivalence</keyword>
</DOC>